NASDAQ:BNTX - BioNTech Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $167.73
  • Forecasted Upside: -41.27 %
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +3.61 (1.28%)

This chart shows the closing price for BNTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioNTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNTX

Analyst Price Target is $167.73
▼ -41.27% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for BioNTech in the last 3 months. The average price target is $167.73, with a high forecast of $248.00 and a low forecast of $104.00. The average price target represents a -41.27% upside from the last price of $285.57.

This chart shows the closing price for BNTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 contributing investment analysts is to hold stock in BioNTech.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/22/2021SVB LeerinkReiterated RatingHoldLow
7/20/2021HC WainwrightReiterated RatingHold$194.00High
7/19/2021Wolfe ResearchInitiated CoverageOutperform$248.00High
7/14/2021HC WainwrightReiterated RatingHold$194.00Low
6/23/2021SVB LeerinkReiterated RatingHoldMedium
6/16/2021Redburn PartnersReiterated RatingNeutral ➝ Sell$146.00High
5/18/2021The Goldman Sachs GroupInitiated CoverageNeutral$173.00Low
5/17/2021Bryan, Garnier & CoReiterated RatingBuy ➝ Neutral$135.00 ➝ $206.00N/A
5/12/2021Canaccord GenuityBoost Price TargetBuy$130.00 ➝ $240.00Low
5/11/2021SVB LeerinkBoost Price TargetPositive ➝ Market Perform$118.00 ➝ $159.00Low
5/11/2021Bryan, Garnier & CoDowngradeBuy ➝ Neutral$135.00 ➝ $206.00Low
4/13/2021SVB LeerinkBoost Price TargetMarket Perform$110.00 ➝ $118.00High
4/6/2021SVB LeerinkBoost Price TargetMarket Perform$106.00 ➝ $110.00Low
4/6/2021Berenberg BankSet Price TargetBuy$130.00Medium
4/6/2021JPMorgan Chase & Co.Set Price TargetNeutral$104.00Medium
3/31/2021JPMorgan Chase & Co.Reiterated RatingNeutral$104.00Low
3/31/2021Berenberg BankReiterated RatingBuy$130.00Medium
2/4/2021SVB LeerinkBoost Price TargetMarket Perform$97.00 ➝ $106.00Low
1/11/2021Berenberg BankSet Price TargetBuy$126.00High
12/15/2020SVB LeerinkBoost Price TargetMarket Perform$91.00 ➝ $97.00Low
12/14/2020Canaccord GenuityBoost Price TargetBuy$115.00 ➝ $130.00High
11/30/2020Bank of AmericaDowngradeBuy ➝ Neutral$123.00 ➝ $126.00High
11/24/2020SVB LeerinkBoost Price TargetMarket Perform$90.00 ➝ $91.00Low
11/16/2020Berenberg BankReiterated RatingBuy$126.00Medium
11/10/2020JPMorgan Chase & Co.Set Price TargetNeutral$90.00Medium
11/10/2020SVB LeerinkBoost Price TargetMarket Perform$64.00 ➝ $90.00High
11/9/2020Canaccord GenuityBoost Price TargetBuy$97.00 ➝ $112.00High
10/29/2020CommerzbankInitiated CoverageBuy$119.00High
10/14/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$62.00 ➝ $69.00High
9/22/2020Berenberg BankReiterated RatingBuy$98.00Medium
8/6/2020SVB LeerinkBoost Price TargetMarket Perform$42.00 ➝ $69.00High
8/3/2020Berenberg BankInitiated CoverageBuy$98.00Medium
7/27/2020HC WainwrightReiterated RatingHoldLow
7/21/2020Canaccord GenuityBoost Price TargetPositive ➝ Buy$75.00 ➝ $97.00Low
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
7/20/2020Bank of AmericaUpgradeNeutral ➝ Buy$71.00 ➝ $105.00Low
7/14/2020HC WainwrightReiterated RatingHoldHigh
7/13/2020Canaccord GenuityBoost Price TargetBuy$60.00 ➝ $75.00Low
7/2/2020Bryan, Garnier & CoBoost Price Target$50.00 ➝ $62.00High
7/2/2020SVB LeerinkBoost Price TargetPositive ➝ Market Perform$37.00 ➝ $42.00High
6/30/2020HC WainwrightDowngradeBuy ➝ NeutralMedium
6/25/2020HC WainwrightLower Price TargetBuy$69.00 ➝ $63.00High
5/19/2020HC WainwrightUpgradeNeutral ➝ Buy$48.00 ➝ $69.00High
4/28/2020Bank of AmericaDowngradeBuy ➝ Neutral$51.00Medium
4/13/2020HC WainwrightReiterated RatingNeutral$30.00 ➝ $48.00High
4/3/2020Canaccord GenuityBoost Price TargetBuy$22.00 ➝ $60.00High
3/18/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$23.00 ➝ $33.00High
3/17/2020HC WainwrightReiterated RatingHold$30.00High
3/9/2020HC WainwrightInitiated CoverageNeutral$30.00High
1/22/2020UBS GroupDowngradeBuy ➝ Neutral$21.00 ➝ $35.00Medium
11/5/2019Wolfe ResearchInitiated CoverageOutperform$21.00 ➝ $21.00Low
11/4/2019SVB LeerinkInitiated CoverageOutperformHigh
11/4/2019Berenberg BankInitiated CoverageBuy$25.00High
11/4/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$21.00 ➝ $21.00High
11/4/2019Canaccord GenuityInitiated CoverageBuy$22.00High
11/4/2019JPMorgan Chase & Co.Initiated CoverageOverweight$23.00High
11/4/2019UBS GroupInitiated CoverageBuy$21.00High
(Data available from 7/26/2016 forward)
BioNTech logo
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Read More

Today's Range

Now: $285.57
Low: $277.21
High: $297.16

50 Day Range

MA: $221.14
Low: $194.50
High: $281.96

52 Week Range

Now: $285.57
Low: $54.10
High: $292.34


125,447 shs

Average Volume

2,571,129 shs

Market Capitalization

$68.97 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of BioNTech?

The following Wall Street sell-side analysts have issued reports on BioNTech in the last year: Bank of America Co., Berenberg Bank, Bryan, Garnier & Co, Canaccord Genuity, Commerzbank AG, HC Wainwright, JPMorgan Chase & Co., Redburn Partners, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for BNTX.

What is the current price target for BioNTech?

11 Wall Street analysts have set twelve-month price targets for BioNTech in the last year. Their average twelve-month price target is $167.73, suggesting a possible downside of 40.5%. Wolfe Research has the highest price target set, predicting BNTX will reach $248.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $104.00 for BioNTech in the next year.
View the latest price targets for BNTX.

What is the current consensus analyst rating for BioNTech?

BioNTech currently has 1 sell rating, 6 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BNTX, but not buy more shares or sell existing shares.
View the latest ratings for BNTX.

What other companies compete with BioNTech?

How do I contact BioNTech's investor relations team?

BioNTech's physical mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The company's listed phone number is 49-61-31908-40 and its investor relations email address is [email protected] The official website for BioNTech is